Pain Therapeutics gained rights to a technology to treat hemophilia from researchers at Stanford University School of Medicine. The company expects to bring it into the clinic in 2008.
"This licensing is part of our strategy to develop novel drug candidates in hematology/oncology, while maintaining a business model that requires a modest outlay of cash," comments Remi Barbier, president and CEO of Pain Therapeutics.
"Over the next 12 months, we plan to develop a novel drug candidate that specifically targets a key mechanism underlying hemophilia," explains Nadav Friedmann, Ph.D., M.D., chief operating and medical officer. "Basic research will continue to be conducted at Stanford, while we focus solely on the initiation of a clinical program."